Lymphoma News

Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).

For more than 23 years, Marla Briskman faced her lymphoma—enduring five relapses and six different treatments. What gave her hope? Incredible treatment advancements and the support of family, friends, and her husband and caregiver, Rickey.

A lymphoma diagnosis not only affects the patient, but their caregivers too. LRF Scientific Advisory Board member, Thomas M. Habermann, MD shares some helpful strategies on how to help cope with some of the pressures of caregiving.

Here are some ways lymphoma patients, survivors and caregivers can best navigate the internet for information, emotional and social support needs.

Belumosudil (REZUROCK, Kadmon Pharmaceuticals, LLC), is a kinase inhibitor for chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older.

On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Milos Miljkovic, MD MSc of the National Cancer Institute Center for Cancer Research discusses the main differences between these types of ALCL, how they are diagnosed, and typical frontline therapies.

On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).